MannKind
Beyond's analysis on MannKind
- — MannKind’s HFSA 2026 data show Furoscix ReadyFlow can manage edema outside the hospital, widening its market opportunity
- — Wells Fargo casts MannKind’s commercial outlook as a “show‑me” story, signaling that the biotech must prove market viability before further investment
Recent news mentioning MannKind
- — MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)
- — MannKind (MNKD) Bets On Inhaled Weight Loss Amid Widening Losses
- — MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management